A Phase I-II Study of Lapatinib and Docetaxel as Neoadjuvant Treatment for HER-2 Positive Locally Advanced/Inflammatory or Large Operable Breast Cancer.

Trial Profile

A Phase I-II Study of Lapatinib and Docetaxel as Neoadjuvant Treatment for HER-2 Positive Locally Advanced/Inflammatory or Large Operable Breast Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2015

At a glance

  • Drugs Docetaxel (Primary) ; Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LAPATAX
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Nov 2015 Accrual to date is 78% according to United Kingdom Clinical Research Network record.
    • 20 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top